NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP
Sol-Gel Technologies Ltd. SLGL
11 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$3.8M
▼ 67.1% vs FY2024
EPS · FY25
$-2.19
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-23.7%
Net margin · FY25
-161.2%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 3.8M
Revenue, FY2025 · full 11-year series below
Revenue
Net income
The company lost 161 cents on every revenue dollar this year.
Per share
USD -2.19
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-23.7%
Return on equity, FY2025
ROE
Operating margin-198.4%
Net margin-161.2%
Return on assets-18.6%
Each USD of equity lost 24 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
−15.2% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
−0.7%
−15.2%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.00B
Shares outstanding, FY2025
Change, 5 years+47.0%
Change, 10 years—
The share count grew 47% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 29.9M
total assets, end of FY2025
Total assetsUSD 29.9M
EquityUSD 22.8M
CashUSD 11.0M
Current ratio4.37×
Equity funds 76% of total assets.
History
11 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
Revenue $B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
·
·
Operating income $B
−0.0
−0.0
−0.0
−0.0
0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EBITDA $B
−0.0
−0.0
−0.0
−0.0
0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
Income tax $B
0.0
0.0
0.0
·
0.0
0.0
0.0
·
·
·
·
Net income $B
−0.0
−0.0
−0.0
−0.0
0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EPS, diluted $
−2.19
−3.79
−10.01
−0.65
0.14
−1.30
−1.26
1.80
5.02
3.30
1.53
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
ROE %
−23.7
−31.4
−67.4
−30.5
6.1
−56.7
−42.3
−574.5
·
·
·
Shares out B
0.00
0.00
0.03
0.02
0.02
0.02
0.02
0.02
0.01
0.01
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
31 of 31
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed